About NovaCell Premium Research Peptide Supplier in Europe About NovaCell Peptides: a science-first, EU-based supplier of high-purity research peptides for biochemical and laboratory research, founded in 2024
What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry
Candidates should also be aware of the limitations of these processes and have reasonable expectations
Reassuring yourself the effects are temporary as your body adjusts
These benefits were accompanied by a significant reduction in the blood levels of homocysteine, a molecule with neurotoxic effects that is elevated in ALS patients and whose conversion into another molecule is dependent on methylcobalamin